SCHEMBL4410117

SCHEMBL4410117

O=C(O)c1n[nH]c2c(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 16/20 0.45
MAPK11 Q15759 5/20 0.45
MAPK13 O15264 3/20 0.45
MAPK12 P53778 3/20 0.45
ALOX5 P09917 2/20 0.45
TGFBR1 P36897 1/20 0.45
KCNH2 Q12809 1/20 0.41
HAO2 Q9NYQ3 1/20 0.40
MAPK10 P53779 1/20 0.39
GCGR P47871 2/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
FRK P42685 1/20 0.39
MAPK9 P45984 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
GSK3B P49841 1/20 0.39
PTK6 Q13882 1/20 0.39
PRKD2 Q9BZL6 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4410189 0.86 MAPK14 (0.48) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL5255490 0.76 MAPK14 (0.61) MAPK14MAPK11MAPK13MAPK12ALOX5
Water SCHEMBL5256024 0.75 MAPK14 (0.59) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL2930737 0.73 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL4407535 0.72 MAPK14 (0.43) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL4406287 0.69 MAPK14 (0.51) MAPK14MAPK11MAPK13MAPK12MAPK10
SCHEMBL4410497 0.69 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL1384949 0.68 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL1384946 0.68 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5
SCHEMBL4411014 0.68 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed
EP-1833828-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS Palau Pharma, S.A. (ES) 2007-09-19 EP claimed
WO-2006013095-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2006-02-09 WO claimed
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed
EP-1833828-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS Palau Pharma, S.A. (ES) 2007-09-19 EP disclosed
WO-2006013095-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK11 42/4885MAPK13 39/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK11 42/4885MAPK13 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.